Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$3.50 -0.4%	$3.48	$2.45 ▼ $4.14	$277.36M	0.25	385,070 shs	248,851 shs
CELU Celularity	$3.15 +2.9%	$2.42	$1.00 ▼ $5.22	$75.44M	0.79	172,791 shs	16,187 shs
FDMT 4D Molecular Therapeutics	$6.54 +6.3%	$4.50	$2.23 ▼ $17.41	$305.32M	2.83	877,916 shs	994,527 shs
GLUE Monte Rosa Therapeutics	$4.45	$4.99	$3.50 ▼ $12.40	$275.14M	1.42	608,003 shs	253,941 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	0.00%	-0.28%	-4.36%	+37.65%	+4.78%
CELU Celularity	-5.26%	-6.99%	+45.02%	+51.49%	+10.47%
FDMT 4D Molecular Therapeutics	+11.21%	+1.65%	+43.69%	+96.49%	-59.00%
GLUE Monte Rosa Therapeutics	+6.21%	-7.87%	-13.76%	+20.27%	+11.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	2.0795 of 5 stars	3.3	0.0	2.0	2.5	1.3
CELU Celularity	0.4241 of 5 stars	0.0	1.0	3.8	1.7	0.0
FDMT 4D Molecular Therapeutics	2.2645 of 5 stars	3.3	3.0	1.5	1.7	0.6
GLUE Monte Rosa Therapeutics	2.4626 of 5 stars	3.3	0.0	2.7	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	71.67% Upside
CELU Celularity	0.00	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	2.64	Moderate Buy	$30.40	365.19% Upside
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$15.33	244.57% Upside

Current Analyst Ratings Breakdown

Latest CELU, FDMT, AVIR, and GLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	FDMT 4D Molecular Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
8/12/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/1/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/29/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$4.59 per share	N/A
CELU Celularity	$54.22M	1.39	N/A	N/A	$0.37 per share	8.51
FDMT 4D Molecular Therapeutics	$40K	7,569.16	N/A	N/A	$11.05 per share	0.59
GLUE Monte Rosa Therapeutics	$75.62M	3.63	N/A	N/A	$4.34 per share	1.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$168.38M	-$1.61	N/A	N/A	N/A	N/A	-32.55%	-30.47%	N/A
CELU Celularity	-$57.89M	-$2.65	N/A	∞	N/A	-106.77%	-271.88%	-42.82%	8/14/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-594,375.81%	-38.38%	-35.02%	8/14/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$72.70M	$0.36	12.38	N/A	N/A	13.58%	9.95%	6.42%	8/14/2025 (Estimated)

Latest CELU, FDMT, AVIR, and GLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.88	-$0.98	-$0.10	-$0.98	$0.52 million	$0.01 million
8/7/2025	Q2 2025	AVIR Atea Pharmaceuticals	-$0.46	-$0.44	+$0.02	-$0.44	N/A	N/A
8/7/2025	Q2 2025	GLUE Monte Rosa Therapeutics	-$0.31	-$0.15	+$0.16	-$0.15	$7.23 million	$23.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CELU Celularity	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.17	19.17
CELU Celularity	4.07	0.38	0.28
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
GLUE Monte Rosa Therapeutics	N/A	7.16	5.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
CELU Celularity	19.02%
FDMT 4D Molecular Therapeutics	99.27%
GLUE Monte Rosa Therapeutics	79.96%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
CELU Celularity	22.10%
FDMT 4D Molecular Therapeutics	9.60%
GLUE Monte Rosa Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	79.36 million	64.99 million	Optionable
CELU Celularity	220	23.95 million	18.66 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.76 million	57.75 million	Optionable

CELU, FDMT, AVIR, and GLUE Headlines

Recent News About These Companies

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

August 7, 2025 | zacks.com

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

August 7, 2025 | globenewswire.com

Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday

August 7, 2025 | marketbeat.com

Readystate Asset Management LP Acquires Shares of 287,000 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

July 23, 2025 | marketbeat.com

Monte Rosa doses first subjects in trial of MRT-8102 for inflammatory conditions

July 22, 2025 | msn.com

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

July 21, 2025 | globenewswire.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 7.3% - Should You Buy?

July 17, 2025 | marketbeat.com

Molecular glue degraders are more versatile than previously thought

July 3, 2025 | cen.acs.orgC

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

July 3, 2025 | globenewswire.com

Monte Rosa’s molecular glue degrader MRT-8102 gains IND clearance for inflammatory conditions

June 12, 2025 | bioworld.comB

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

June 10, 2025 | globenewswire.com

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Roche strikes Orionis deal to develop ‘molecular glues’ for cancer

May 21, 2025 | biopharmadive.comB

Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates

May 8, 2025 | zacks.com

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

May 8, 2025 | globenewswire.com

Why Monte Rosa Therapeutics, Inc.’s (GLUE) Stock Is Down 6.04%

May 6, 2025 | aaii.comA

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

April 28, 2025 | globenewswire.com

Monte Rosa Therapeutics Insider Ups Holding During Year

April 22, 2025 | finance.yahoo.com

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Acquires $58,400.00 in Stock

March 26, 2025 | insidertrades.com

Monte Rosa Therapeutics: Exercise Extreme Caution

March 25, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU, FDMT, AVIR, and GLUE Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$3.50 -0.02 (-0.43%)

As of 02:05 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Celularity NASDAQ:CELU

$3.15 +0.09 (+2.94%)

As of 01:54 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

4D Molecular Therapeutics NASDAQ:FDMT

$6.54 +0.39 (+6.26%)

As of 02:06 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.45 0.00 (0.00%)

As of 02:06 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time